表皮生长因子受体在非小细胞肺癌的研究进展  

Research progress of epidermal growth factor receptor in non-small cell lung cancer

作　　者：杨雪琴[1] 邹长武 YANG Xueqin;ZOU Changwu(Institute for Cancer Research&Medical school of Jingchu University of Technology,Hubei,Jingmen 448000,China)

机构地区：[1]湖北省荆楚理工学院医学院/荆楚理工学院肿瘤临床防治研究所,448000 [2]湖北省荆门市第二人民医院肿瘤中心

出　　处：《河北医药》2021年第20期3157-3163,共7页Hebei Medical Journal

基　　金：湖北省高等学校优秀中青年科技创新团队计划项项目(编号:T201819)。

摘　　要：肺癌是一种发病率和死亡率最高的恶性肿瘤。非小细胞肺癌(non-small cell lung cancer,NSCLC)占肺癌的80%~85%。表皮生长因子受体(epidermal growth factor,EGFR)是一类具有酪氨酸激酶活性的细胞膜表面受体,其介导的信号转导与肿瘤细胞的生长、增殖、分化、凋亡、转移等过程密切相关。靶向EGFR酪氨酸激酶抑制剂已经成为抗肿瘤药物研究的热点,并研发出许多有价值的药物在临床使用。有EGFR基因突变的NSCLC患者已从该靶向治疗中获益。本文对NSCLC中EGFR基因突变及基因突变相关的靶向药物研究进展进行综述。Lung cancer is a malignant tumor with the highest incidence rate and mortality rate,in which non-small cell lung cancer(NSCLC)accounts for 80%~85%.The epidermal growth factor receptor(EGFR),a receptor on the cell membrane surface,has tyrosine kinase activity.The signal transduction mediated by EGFR is closely related to the growth,proliferation,differentiation,apoptosis and metastasis of tumor cells.The target-EGFR inhibitors have been a hotspot in the researches about anti-tumor drugs,and many valuable drugs have been developed.The target-EGFR therapy has brought great clinical benefit to NSCLC patients with EGFR mutations.This article reviews the research progress of EGFR mutations and related EGFR-TKIs in NSCLC.

关 键 词：非小细胞肺癌 表皮生长因子受体 基因突变 靶向治疗 酪氨酸激酶抑制剂 

分 类 号：R734.2[医药卫生—肿瘤]